Please assess the completion status of the following clinical trial:

Trial Title: Rituximab to Treat Severe Hemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe congenital hemophilia A~* Documented historical inhibitor titer to factor VIII of at least 5 BU/mL~* Inhibitor level greater than or equal to 5 BU/mL 5 to 14 days after initial factor VIII exposure during screening~Exclusion Criteria:~* Known hypersensitivities or allergies to murine and/or humanized antibodies~* Currently participating in investigational hemophilia studies~* HIV infected~* Any immunodeficiency disorder~* Liver disease and serum ALT or AST is greater than three times the upper limit of normal, albumin is less than 2.5g/dl, and/or INR is greater than 1.7~* Received interferon or other immunomodulatory drugs, such as steroids or cytotoxic therapy in the 30 days prior to study entry~* History of cardiac arrhythmias, any active febrile illness, kidney insufficiency, or pulmonary infiltrates~* Has previously received rituximab treatment~* Currently undergoing immune tolerance therapy~* Evidence of Hepatitis B (HBV) infection, defined as one of the following:~  * HBsAg positive~ * HBsAg negative, HBsAb negative, HBcAb positive, and HBV DNA positive~* Participants with a high responding inhibitor (at least 5 BU/mL) first detected fewer than 12 months prior to study entry, unless the participant has failed immune tolerance therapy, defined as one of the following:~  1. Failure to fulfill the criteria for full or partial success within 33 months, as defined by a factor VIII recovery greater than or equal to 66% of expected and half-life greater than or equal to 6 hours measured after a 72-hour treatment-free washout period~ 2. Failure to achieve greater than 20% reduction in inhibitor titer during each interim non-overlapping 6-month period of ITT in the absence of documented infection, with 9 months as the minimum treatment period and 33 months as the maximum possible duration of unsuccessful ITT~ 3. Withdrawal from ITT for any other reason~* Routinely receive factor VIII concentrate for the treatment of both major and minor bleeding events~* Has received factor VIII concentrate in the 7 days prior to study entry

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): Rituximab administered at a dose of 375 mg/m2 by slow intravenous infusion once per week for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).